Skip to main content
. 2017 May 19;8(26):43237–43247. doi: 10.18632/oncotarget.18018

Figure 5. Effects of ABCG2 knockdown on ROS and apoptotic mechanisms upon DMC treatment.

Figure 5

(A) FACS analysis of ROS levels determined in GSCs transfected with or without lenti-GFP-ABCG2 shRNA and treated with 30μM DMC. (B) MTT assay analyzing cell growth inhibition rate in GSCs transfected with lenti-GFP-ABCG2 shRNA and treated with 30μM DMC in presence or absence of 10mM NAC. (C) Western blot analysis of Cyt c in GSCs transfected with or without lenti-GFP-ABCG2 shRNA and treated with 30μM DMC. (D) Caspase-3 activity assay in GSCs transfected with or without lenti-GFP-ABCG2 shRNA and treated with 30μM DMC.